Search Results

Your search matched 5 results

#1

January Drug Price Increases Fuel Continued Scrutiny; Underscores Need to Communicate Pricing Factors | Blog

With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.

#2

State-Level Drug Pricing Policy Accelerating: Life Sciences Companies Can Contextualize Value & Access to Policymakers | Blog

While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.

#3

ICER Policy Proposals for Orphan Drug Pricing | Blog

The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”

#4

What the CMS National Coverage Decision Means for the Life Science Industry   | Blog

What the CMS National Coverage Decision Means for the Life Science Industry  

#5

Health Equity, Real-World Evidence: A Trend to Watch | Blog

The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.